A data manager for a European organisation of doctors

The EPSSG, the European association of paediatric oncologists specialised in soft tissue sarcoma, recently completed a large-scale clinical trial on rhabdomyosarcomas. That trial, which started in 2005, recently included its last patients in December 2016 and allowed the collection of molecular, genetic and clinical data from 2 000 patients.

 

KickCancer wants to support the EPSSG to have those data analysed by funding the salary of a data manager for 3 years. The in-depth analysis of those data will result in the validation of a new risk assessment and classification method, which would be uniform across the world. This new classification will contribute to an improved treatment of the patients according to their risk group.

 

First results: two subgroups of patients have already changed risk category. Specifically, in the new treatment protocol, a first category of children was transferred from the “high risk” to the “standard” risk group, which justifies the use of lighter treatments in the hope of reducing the long-term side effects caused by the treatments. On the other hand, a second category of patients was transferred to a higher risk group and will receive a heavier treatment in the hope of improving their survival chances. 

 

Status and next steps: there will be two interim reports published in April 2019 and 2020; a final report on the projects is expected in the Spring of 2021. 

Objectives

100%
Objective: 93 000 euros over 3 years
More than 95% of your donations go to financing research and supporting our advocacy work, less than 5% go to administration.
Donate

Our other projects

Liquid biopsies

For children with rhabdomyosarcoma, assessing response to treatment and whether they remain in remission requires regular imaging such as MRI. In some types of cancer, but not rhabdomyosarcoma, it has been shown to be clinically useful to assess abnormal DNA released from a cancer into the blood stream.

View the project
91%
150 000 over 1 year
Donate

A better cure for an incurable brain tumour

Brain tumours are the main causes of mortality and morbidity of children, adolescents and young adults. Gliomas are the most frequent and the most fatal kind, among which the diffuse intrinsic pontic gliomas (or DIPG) represents the most severe form, universally incurable with hardly any patients surviving more than 2 years after the diagnosis.

View the project
100%
150 000 over 1 year
Donate